The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Racil
Zdenek
Z
Razga
Filip
F
Buresova
Lucie
L
Jurcek
Tomas
T
Dvorakova
Dana
D
Zackova
Daniela
D
Timilsina
Shira
S
Cetkovsky
Petr
P
Mayer
Jiri
J
D001549:Benzamides; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D007958:Leukocyte Count; D007962:Leukocytes / Q000166:cytology*; D007963:Leukocytes, Mononuclear; D009504:Neutrophils; D027702:Organic Cation Transporter 1 / Q000235:genetics*; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000032:analysis*; D012334:RNA, Neoplasm / Q000032:analysis
D001549:Benzamides; D027702:Organic Cation Transporter 1; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000068877:Imatinib Mesylate